GeorgeKPhilipsMDMBBS, MPH

Professor of Medicine & Vice-Chair (Department of Medicine), Attending Physician in Genitourinary Medical Oncology (Georgetown University Hospital, Washington Cancer Institute and Lombardi Comprehensive Cancer Center)

Join to view full profile

Dr. Philips is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Philips' full profile

Already have an account?

Office
3800 Reservoir Rd Nw
Lombardi Cancer Center
Washington, DC 20007
Phone+1 202-444-2223

Fax+1 202-444-9429

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 1990 - 1995
Grant Medical CollegeClass of 1986

Certifications & Licensure

DC State Medical License 2010 - 2024
MD State Medical License 2010 - 2013
VT State Medical License 1999 - 2012
CO State Medical License 1990 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2

Publications & Presentations

PubMed

3 citations
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan
The Oncologist. 2023-04-06
8 citations
STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Ann Taber, Youngrok Park, Alana Lelo, Frederik Prip, Jerry Xiao
Urologic Oncology. 2021-07-01
89 citations
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta
Journal of Clinical Oncology. 2020-04-09

Journal Articles

STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer
Ciaran Mannion, George Philips, Brent T Harris, Pritish Bhattacharyya, Jeffry Simko, Clinical Cancer Research